New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the ₹13,630 crore deal to acquire Bharat Serums and Vaccines (BSV), senior company officials said.
The deal potentially opens doors for Mankind Pharma to the overseas markets, which currently draws 92 per cent of its revenues from India.
The combined entity will draw around 13 per cent revenues from the international market, with the remaining coming from the domestic market.
BSV draws around 46 per cent of revenues from international markets, with the remainder from the Indian market. Rajeev Juneja, vice-chairman and managing director, Mankind Pharma, said BSV's portfolio allows them to enter the branded international business with products that have a high entry barrier or are considered superspeciality.
"In some products, we would be the only ones in the market, while in others, there would be limited competition of one or two players," Juneja said.
The deal is expected to be closed in three to four months and will be funded through internal accruals and a mix of debt and equity.
This story is from the July 27, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the July 27, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Avoid partial payout: Buy health cover with fewer sub-limits
At a recent Confederation of Indian Industry (CII) summit, Satyajit Tripathi, member (distribution), Insurance Regulatory and Development Authority of India (Irdai), highlighted that grievances in general insurance, especially health insurance, mainly revolve around claim payments.
'Largecaps appear reasonably valued'
Investors entering equities should come in with a long-term horizon to ensure short-term fluctuations amid high valuations do not derail the wealth generation, says DEEPAK SHENOY, chief executive officer and founder of Capitalmind.
Sustained FPI activity lifts Sensex, Nifty
Equity benchmark index Sensex rebounded nearly 100 points to hit a lifetime closing high on Monday and Nifty scaled an intraday record level, propelled by bargain hunting in energy, utility and banking stocks amid sustained foreign fund inflows.
Investors may book partial profit: Brokerages
Analysts on Monday attributed the blockbuster debut of Bajaj Housing Finance Ltd (BHFL) on the bourses to its strong fundamentals and the brand 'Bajaj', and said it could emerge as a long-term wealth creator.
Interest, trust of investors humbling: Sanjiv Bajaj
Sanjiv Bajaj, chairman and managing director of Bajaj Finserv, on Monday said he expected 12-15 per cent credit growth in the housing finance industry, amid the strong tailwinds in the economy.
Trent may replace Bajaj Finserv in Sensexrejig in December
Bajaj Housing Finance Ltd's impressive stock market debut has brought cheer to the 100year-old Bajaj Group, but the conglomerate faces the prospect of Bajaj Finserv being removed from the benchmark Sensex index.
Sebi withdraws earlier statement on staff unrest
The Securities and Exchange Board of India (Sebi) on Monday said it was amicably addressing the concerns of its protesting employees on \"internal\" matters, as it withdrew an earlier press release that claimed that its staff's complaints were influenced by external elements.
The clash of 'will'power: The jury is still out
Following courtroom drama, experts analyse which one will dominate legal proceedings
FIRST LINE OF DEFENCE
Why New Delhi is underlining the role of border villages as custodians of India's frontiers
A fine balance
Markets in agriculture must be allowed to function
